Esperion Therapeutics (NASDAQ:ESPR) reported Q4 EPS of $, $0.85 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $0 versus the consensus estimate of $20.57 million.
Esperion Therapeutics (NASDAQ:ESPR) reported Q4 EPS of $, $0.85 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $0 versus the consensus estimate of $20.57 million.